2023-03-232024-03-312024-03-31false14752534REALIGN HEALTH LTD2024-09-16iso4217:GBPxbrli:pure147525342023-03-23147525342024-03-31147525342023-03-232024-03-31147525342023-03-22147525342023-03-22147525342023-03-222023-03-2214752534bus:SmallEntities2023-03-232024-03-3114752534bus:AuditExempt-NoAccountantsReport2023-03-232024-03-3114752534bus:FullAccounts2023-03-232024-03-3114752534bus:PrivateLimitedCompanyLtd2023-03-232024-03-3114752534core:WithinOneYear2024-03-3114752534core:AfterOneYear2024-03-3114752534core:WithinOneYear2023-03-2214752534core:AfterOneYear2023-03-2214752534core:ShareCapital2024-03-3114752534core:SharePremium2024-03-3114752534core:RevaluationReserve2024-03-3114752534core:OtherReservesSubtotal2024-03-3114752534core:RetainedEarningsAccumulatedLosses2024-03-3114752534core:ShareCapital2023-03-2214752534core:SharePremium2023-03-2214752534core:RevaluationReserve2023-03-2214752534core:OtherReservesSubtotal2023-03-2214752534core:RetainedEarningsAccumulatedLosses2023-03-2214752534core:LandBuildings2024-03-3114752534core:PlantMachinery2024-03-3114752534core:Vehicles2024-03-3114752534core:FurnitureFittings2024-03-3114752534core:OfficeEquipment2024-03-3114752534core:NetGoodwill2024-03-3114752534core:IntangibleAssetsOtherThanGoodwill2024-03-3114752534core:ListedExchangeTraded2024-03-3114752534core:UnlistedNon-exchangeTraded2024-03-3114752534core:LandBuildings2023-03-2214752534core:PlantMachinery2023-03-2214752534core:Vehicles2023-03-2214752534core:FurnitureFittings2023-03-2214752534core:OfficeEquipment2023-03-2214752534core:NetGoodwill2023-03-2214752534core:IntangibleAssetsOtherThanGoodwill2023-03-2214752534core:ListedExchangeTraded2023-03-2214752534core:UnlistedNon-exchangeTraded2023-03-2214752534core:LandBuildings2023-03-232024-03-3114752534core:PlantMachinery2023-03-232024-03-3114752534core:Vehicles2023-03-232024-03-3114752534core:FurnitureFittings2023-03-232024-03-3114752534core:OfficeEquipment2023-03-232024-03-3114752534core:NetGoodwill2023-03-232024-03-3114752534core:IntangibleAssetsOtherThanGoodwill2023-03-232024-03-3114752534core:ListedExchangeTraded2023-03-232024-03-3114752534core:UnlistedNon-exchangeTraded2023-03-232024-03-3114752534core:MoreThanFiveYears2023-03-232024-03-3114752534core:Non-currentFinancialInstruments2024-03-3114752534core:Non-currentFinancialInstruments2023-03-2214752534dpl:CostSales2023-03-232024-03-3114752534dpl:DistributionCosts2023-03-232024-03-3114752534core:LandBuildings2023-03-232024-03-3114752534core:PlantMachinery2023-03-232024-03-3114752534core:Vehicles2023-03-232024-03-3114752534core:FurnitureFittings2023-03-232024-03-3114752534core:OfficeEquipment2023-03-232024-03-3114752534dpl:AdministrativeExpenses2023-03-232024-03-3114752534core:NetGoodwill2023-03-232024-03-3114752534core:IntangibleAssetsOtherThanGoodwill2023-03-232024-03-3114752534dpl:GroupUndertakings2023-03-232024-03-3114752534dpl:ParticipatingInterests2023-03-232024-03-3114752534dpl:GroupUndertakingscore:ListedExchangeTraded2023-03-232024-03-3114752534core:ListedExchangeTraded2023-03-232024-03-3114752534dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-03-232024-03-3114752534core:UnlistedNon-exchangeTraded2023-03-232024-03-3114752534dpl:CostSales2023-03-222023-03-2214752534dpl:DistributionCosts2023-03-222023-03-2214752534core:LandBuildings2023-03-222023-03-2214752534core:PlantMachinery2023-03-222023-03-2214752534core:Vehicles2023-03-222023-03-2214752534core:FurnitureFittings2023-03-222023-03-2214752534core:OfficeEquipment2023-03-222023-03-2214752534dpl:AdministrativeExpenses2023-03-222023-03-2214752534core:NetGoodwill2023-03-222023-03-2214752534core:IntangibleAssetsOtherThanGoodwill2023-03-222023-03-2214752534dpl:GroupUndertakings2023-03-222023-03-2214752534dpl:ParticipatingInterests2023-03-222023-03-2214752534dpl:GroupUndertakingscore:ListedExchangeTraded2023-03-222023-03-2214752534core:ListedExchangeTraded2023-03-222023-03-2214752534dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-03-222023-03-2214752534core:UnlistedNon-exchangeTraded2023-03-222023-03-2214752534core:NetGoodwill2024-03-3114752534core:IntangibleAssetsOtherThanGoodwill2024-03-3114752534core:LandBuildings2024-03-3114752534core:PlantMachinery2024-03-3114752534core:Vehicles2024-03-3114752534core:FurnitureFittings2024-03-3114752534core:OfficeEquipment2024-03-3114752534core:AfterOneYear2024-03-3114752534core:WithinOneYear2024-03-3114752534core:ListedExchangeTraded2024-03-3114752534core:UnlistedNon-exchangeTraded2024-03-3114752534core:ShareCapital2024-03-3114752534core:SharePremium2024-03-3114752534core:RevaluationReserve2024-03-3114752534core:OtherReservesSubtotal2024-03-3114752534core:RetainedEarningsAccumulatedLosses2024-03-3114752534core:NetGoodwill2023-03-2214752534core:IntangibleAssetsOtherThanGoodwill2023-03-2214752534core:LandBuildings2023-03-2214752534core:PlantMachinery2023-03-2214752534core:Vehicles2023-03-2214752534core:FurnitureFittings2023-03-2214752534core:OfficeEquipment2023-03-2214752534core:AfterOneYear2023-03-2214752534core:WithinOneYear2023-03-2214752534core:ListedExchangeTraded2023-03-2214752534core:UnlistedNon-exchangeTraded2023-03-2214752534core:ShareCapital2023-03-2214752534core:SharePremium2023-03-2214752534core:RevaluationReserve2023-03-2214752534core:OtherReservesSubtotal2023-03-2214752534core:RetainedEarningsAccumulatedLosses2023-03-2214752534core:NetGoodwill2023-03-2214752534core:IntangibleAssetsOtherThanGoodwill2023-03-2214752534core:LandBuildings2023-03-2214752534core:PlantMachinery2023-03-2214752534core:Vehicles2023-03-2214752534core:FurnitureFittings2023-03-2214752534core:OfficeEquipment2023-03-2214752534core:AfterOneYear2023-03-2214752534core:WithinOneYear2023-03-2214752534core:ListedExchangeTraded2023-03-2214752534core:UnlistedNon-exchangeTraded2023-03-2214752534core:ShareCapital2023-03-2214752534core:SharePremium2023-03-2214752534core:RevaluationReserve2023-03-2214752534core:OtherReservesSubtotal2023-03-2214752534core:RetainedEarningsAccumulatedLosses2023-03-2214752534core:AfterOneYear2023-03-232024-03-3114752534core:WithinOneYear2023-03-232024-03-3114752534core:Non-currentFinancialInstrumentscore:CostValuation2023-03-232024-03-3114752534core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-03-232024-03-3114752534core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-03-232024-03-3114752534core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-03-232024-03-3114752534core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-03-232024-03-3114752534core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-03-232024-03-3114752534core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-03-232024-03-3114752534core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-03-232024-03-3114752534core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-03-232024-03-3114752534core:Non-currentFinancialInstrumentscore:CostValuation2024-03-3114752534core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-03-3114752534core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-03-3114752534core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-03-3114752534core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-03-3114752534core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-03-3114752534core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-03-3114752534core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-03-3114752534core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-03-3114752534core:Non-currentFinancialInstrumentscore:CostValuation2023-03-2214752534core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-03-2214752534core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-03-2214752534core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-03-2214752534core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-03-2214752534core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-03-2214752534core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-03-2214752534core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-03-2214752534core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-03-2214752534bus:Director12023-03-232024-03-31

REALIGN HEALTH LTD

Registered Number
14752534
(England and Wales)

Unaudited Financial Statements for the Period ended
31 March 2024

REALIGN HEALTH LTD
Company Information
for the period from 23 March 2023 to 31 March 2024

Director

BINDER, Benjamin Leslie

Registered Address

C/O Census Accountancy
13 West Street
Dunstable
LU6 1SX

Registered Number

14752534 (England and Wales)
REALIGN HEALTH LTD
Balance Sheet as at
31 March 2024

Notes

2024

£

£

Current assets
Debtors7,384
Cash at bank and on hand126
7,510
Creditors amounts falling due within one year3(7,477)
Net current assets (liabilities)33
Total assets less current liabilities33
Net assets33
Capital and reserves
Profit and loss account33
Shareholders' funds33
The financial statements were approved and authorised for issue by the Director on 16 September 2024, and are signed on its behalf by:
BINDER, Benjamin Leslie
Director
Registered Company No. 14752534
REALIGN HEALTH LTD
Notes to the Financial Statements
for the period ended 31 March 2024

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in accordance with the Companies Act 2006 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.
Revenue from rendering of services
Revenue from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. Turnover is only recognised to the extent of recoverable expenses when the outcome of a contract cannot be estimated reliably.
2.Average number of employees

2024
Average number of employees during the year0
3.Creditors: amounts due within one year

2024

£
Taxation and social security7,477
Total7,477